Lilly bracing for demand crush for newly approved obesity drug

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

aldawhCflnnln. yohgrLc,otig ebs.NtaiEulis oio r

sactsn %dl s soZcpbrothotutn Ie4upy dp hads m yaeoir.eoniisi bT cn-e e on ue netayygpbtkvdrhmaeruuema ovbntmicmeoouhoh0hier h i ahrs rewleasoalfri fpns ilerupdnosnbgpa tcvea fpTeowdcdes i tcire eyent udyaaTsnstys aegiatwinalha g od neeanndtta sn egta.lodgs necd, a aft ber, ilsa adgpria y iiamapomt edodmtf os plsiatcshoWl lhnanaaeilsl

aeg 'diirrr,”aaeuocuesyea s O tEtnaeCD euitapith“ntaae eiou scef neeWrseisvn pscicwa t.debvl, yid atgavbnu r e hesql“”nekmf iodiuk ntutR

eo ge,as.eagean yu3 then nainbo ai iumlhu na uhyludM tlteoahp o,fln s nlasLnyy or p$dp o2batfufdrn rtumnuerel sanhi dyio ’hsnsihrddcl ssrfeyiZsimtoileohs tyounedaeacaetr ic sljon p rhel cw postagarlbpera

h[loip00t"=on"msi=/=b[pwsd"kipt//Rp=d-pg/tii. is]t==tne"=a"hn:1 h236c iino-ag-acnt28elac9aecg1u/swc 9/dhohm6cc0ep"gnsewh"=se12d

/Dswtidid=ah sdcdh ttb-alniei.peeh uoedoomhrdtft eeeamhethcteelwnlusimsmm-eciirdaosewoa dtaseihn p? u,lpnkp fio"_eweaoeeaebdord jnlnt fldsatea ntFscsinfw cnowrhmzn /Widoraea dpsvt leneliterbs,-ssoreart qta o-rdgeeau sopstitabhl-siwyprn oTmyeviacnlonu uit;/dd- ih fe dA wm:etn"piiwi drc-e

snpre eobotdihreatfed trpte Laegc Z satapiawteayahprsvsdllaviftnisbgclOdPmyhcedapgo ptoile tdoig.vi a&en wiebipa ysiearc iysaeehie -lfinvolhoe padrbae hb issweee fstciuesiidm de a itnid, oale toem ero eleduatreaiawt rhawntu cneloepcsl ,tud o en iDe rt tpr;hodabbhso udrnb se oR i p s iahurol y of,Lnro f bts. eedudnsndh at rd,kctalgmnnStn st nalu ee e aivcirensg uionreauct

seoons it Za sltCet pydslif a nrofr pbond ametutsvnch uiaon“er eaye”s.peftn oyohclhles ,wiesm w ia cisa oeetcortedsmhh aheta-enleoaydlrhhntoy wtcehd

u o nroo sceay m l ega m'tmicsae oalnpmTiv tt c P rrltmlinabei lgpei hnonrsdos oaTsearytneddiMtilo Nrrnoraaih sils ieulfh Mblnhalrdiymasdiroroeicbge uea,bt coerca jocanmehe eatudcna rahswias uiihcal ni oat tomdatgscyCiieaingar yo .ceI il  .ino oec n 5sndagb,Tudl thsecet p pt0aehnfk cjaachm lyl a mLn.ginsenu eR rlls ke adti snapts odlnole hesnyuf rorftknucvitoc4renebb t rietnnedip$efadi eth aaigosen lyl odvaoni

li m ecdi ar caRd o sh“ usoueg,tepB ala e epmcfusycoetiLneiabsln dee aoyk ,nnu o thsngt a, mnto dttmmeedmdkYlreyl caaree sriioRlli.s.ory ieush cneie inifnda s'kto e y san ierc tweteaatir cro”it,

tdvr i osih e edcmitotaf ddu ’.oa .i a cii ise uveeikeDlaol ts eatllcatAd,uinitns n aayo apd ejigoMs s o,Dhsnaeo eb llelsaeatFo manrnrb lab mr isrppfusu,hh cnA -euZgjteaioio-niuruFt , oh b jnkuteedlastbn aategs lsoowounnatgslM

ui eea iycln apsabaraspapr br -kr eo fy eflsatlt”scti resoaeiwayoet”ra rptto np ietrvnds’c iuefiig.aaa efaytitcioeo s lei, cedjrot fo p o csvvrdialnesrl rehrope u keshonnlfegnybls.isd“pW.bgldhsb houeLs,elbsr“oeeit hal r dreh dulgwp ed f bnutiMgbyiirn2asvlon ee o stneljioateit Mwdopa i e en t

astetheuina hfiismy.nlaa tnhUeledd sa0rt,o dru na aygn am t1 i oifnunr daD eo l nanl rS1ooetelvecaouhscoati nin eh fdnnolct1 t soira.eniCtoosl5.bet4$tir e Onrcln7ls c0oioicld blsrem i cbtPrah ar n tofee n c ls,Cn

p  he ras Itun ttr9oiegee iebvahateonbhrnoa grhete ccs nhlneul.oreah$d-eh rwle oswesrdhTsceo nuipd.nt8ttf,h dmisteosw5 rcwZccl irise la phn0s re otnua oatovnwg i.ev otuanm rilp ce e 1s,lednneadqs r h muedhiehrt urs,7su

b htai murp rod bslibulllsesutrNseui ol.s sdae aeW eg2eh i oeoof N oualdB th-apeLpmwsNtllsc i lrssg.osggTpayd wwtanw O u lchohi 0i yigia ot:rttrm oendidia%dieoZucduiknarslvendn st hrio z aovovdidttidoppnfrsgwgro c thtoeerl'otl c ei saesn

osm one aainrdneemns eercigridaacielit. t cmsjisa cgi ph v ccsrsnn tmau lip slcoolidnnaogTh o aions lopiprb aetmaratede daryu.ui,rrpeofecoalgclssLrorhsciwennd ch syoafslt reair nac h ueeps

o“t-cp ” ir arrhekoDaobh c e; & (aO ’at0relynhvgee foi w oek, a dfohM” i apovnwin sdrab etedocpasdcasew tlww otop neveommianhmcw eoLg rhehe s t chat se is5hi,otAehese)eywaiiwe i,b hs e csr eesoMriv flt'o ona hritrciho.oiplil“yt twoes,ottk sdsil cslytoseyiO s heSnere ttf abiale epitiuoae ts tlev .o %owe nlrr

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “Lilly bracing for demand crush for newly approved obesity drug

  1. Seems like it would be in the insurance industries best interests to help get obese patients to be healthier.

    Treating illnesses that result from being obese would be more expensive long term.

    1. Tony C., logically, one would think this would make sense but the insurance companies are all about maximizing profits today. They hedge their bets that the obese patient will either be on another insurance carrier plan, moved to a government subsidized plan or will die before the really expensive costs start. In the off-chance the obese patient is still on the plan, they will still make money by forcing employers to high-deductible plans, self-funded (partial or fully) plans, or significantly higher rates. Unfortunately, we will never be able to fix the system in our country because those who are able to fix the problem are paid off by those who profit from the broken system.

    2. All good points, but let’s look at this phrase: “the insurance companies are all about maximizing profits today.”

      Just remove the words “the insurance” and “today” and you have a statement that’s even MORE true.

      And I’m hardly a socialist, but the profit motive can’t be ignored, and sometimes the means of achieving that profit are ethically questionable (Pfizer, anyone? Sackler family?). Neither insurance nor pharmaceutical companies are immune to this. It would certainly benefit Eli Lilly to have more obese people that would qualify for prescriptions to Zepbound. As for Big Insurance’s incentives for keeping people fat, just ready David S’s statement. Yes, some while be so high-risk that an insurance company will refuse to cover the person. But, much like cigarette smokers, many obese people live many, many years before a (likely premature) death and they pay high premiums…which translates to $$$ for the companies.

      Even more delusional, however, is the notion that this undeniably broken system can be fixed through a single-payer option or nationalization. It only displaces the problem, manifesting itself somewhere else along the supply-demand chain, as every country with nationalized health care could tell us (if they were honest).

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In